Lucia Parlati
Overview
Explore the profile of Lucia Parlati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramier C, Protopopescu C, Di Beo V, Parlati L, Marcellin F, Carrat F, et al.
Liver Int
. 2025 Mar;
45(4):e70065.
PMID: 40087922
Background And Aims: Early assessment of hepatocellular carcinoma (HCC) risk could improve long-term outcomes in people with chronic hepatitis B virus (HBV) infection. Some existing HCC predictive scores are not...
2.
Barat M, Ollivier C, Taibi L, Nitsche V, Sogni P, Soyer P, et al.
Diagn Interv Imaging
. 2024 Oct;
106(3):93-97.
PMID: 39358154
Purpose: The purpose of this study was to compare levels of pain and anxiety during percutaneous ultrasound-guided liver biopsy between patients receiving standard of care and those receiving standard of...
3.
Barre T, Parlati L, Bourliere M, Ramier C, Marcellin F, Protopopescu C, et al.
J Viral Hepat
. 2024 Sep;
31(12):830-846.
PMID: 39252600
Although Hepatitis C virus (HCV) infection can be cured with direct-acting antivirals (DAA), some cured patients face a serious risk of advanced liver damage and early mortality. In order to...
4.
Parlati L, Mouliade C, Nguyen Khac E, Collier M, Tzedakis S, Bouam S, et al.
Clin Gastroenterol Hepatol
. 2024 Aug;
PMID: 39209197
Background & Aims: There is limited understanding of the benefits of alcohol rehabilitation after alcohol hepatitis (AH). Methods: We conducted a 2012 to 2021 national longitudinal study involving adult inpatients...
5.
Ortega-Prieto P, Parlati L, Benhamed F, Regnier M, Cavalcante I, Montabord M, et al.
JHEP Rep
. 2024 Jul;
6(6):101076.
PMID: 38978772
[This corrects the article DOI: 10.1016/j.jhepr.2023.100878.].
6.
Parlati L, Regnier M, Benhamed F, Issad T, Postic C
Med Sci (Paris)
. 2024 Feb;
40(2):137-139.
PMID: 38411418
No abstract available.
7.
Ortega-Prieto P, Parlati L, Benhamed F, Regnier M, Cavalcante I, Montabord M, et al.
JHEP Rep
. 2024 Feb;
6(2):100878.
PMID: 38298740
Background & Aims: -GlcNAcylation is a reversible post-translational modification controlled by the activity of two enzymes, -GlcNAc transferase (OGT) and -GlcNAcase (OGA). In the liver, -GlcNAcylation has emerged as an...
8.
Barre T, Bourliere M, Parlati L, Ramier C, Marcellin F, Protopopescu C, et al.
Drug Alcohol Rev
. 2023 Dec;
43(3):718-731.
PMID: 38133601
Introduction: The risk of mortality in people with a history of injection drug use (PHID) is high, as is the prevalence of hepatitis C virus (HCV) infection. Although direct-acting antivirals...
9.
Parlati L, Sakka M, Retbi A, Bouam S, Hassani L, Meritet J, et al.
JHEP Rep
. 2023 Dec;
5(12):100880.
PMID: 38074948
Background & Aims: There is concern about the burden of liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). Methods: In a retrospective cohort study, we evaluated...
10.
Hedjoudje M, Barat M, Dohan A, Lucas A, Dautry R, Coriat R, et al.
Can Assoc Radiol J
. 2023 Aug;
75(1):178-186.
PMID: 37563785
Purpose: The purpose of this study was to compare the technical success rate, the selectivity of transarterial chemoembolisation (TACE), the complication rate, the radiation dose given to the patients and...